Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV8ZFA)

Drug Name
PMID20080612C1 Drug Info
Synonyms
BAS 00486818; tg3-95-1; 301322-12-3; AC1LDROW; Oprea1_785181; Oprea1_405733; MLS000107338; GTPL5819; ZINC35938; MolPort-000-222-632; CHEBI:112974; HMS2485P23; CCG-17500; BDBM50016951; STK386484; AKOS000513935; MCULE-3137850852; SMR000111709; ST005800; KB-275480; SR-01000448413; SR-01000448413-1; F0817-0357; ethyl 2-(furan
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
673766
ChEBI ID
CHEBI:112974
TTD Drug ID
DMV8ZFA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [3]
Alprostadil DMWH7NQ Aorta coarctation Approved [4]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [5]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [6]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [7]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [8]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [9]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [10]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Modulator (allosteric modulator) [1]

References

1 Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2307-12.
2 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
4 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
5 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
6 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
7 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
8 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
9 Pfizer. Product Development Pipeline. March 31 2009.
10 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
11 Clinical pipeline report, company report or official report of Tempest Therapeutics.